Alcobra Ltd. (ADHD) Tops Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
- SanDisk upgraded at JPMorgan after investor day; shares climb
Alcobra Announces Fourth Quarter and Fiscal 2015 Financial Results and Provides Corporate Update
February 17, 2016 8:00 AM ESTConference Call & Webcast February 17th at 8:30 a.m. Eastern Time/5:30 a.m. Pacific Time
TEL AVIV, Israel, Feb. 17, 2016 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq: ADHD), an emerging pharmaceutical company focused on the development of new medications to treat patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome (Fragile X), today announced financial results for the three and twelve months ended December 31, 2015, and provided a corporate update.
Fourth Quarter and Fiscal Year Ended December 31, 2015 Financial Results:
Total operating expenses in the... More